Can MD Hyperbaric turn medical-grade HBOT into a mainstream recovery clinic model?
HBOT demand is rising beyond hospitals. MD Hyperbaric’s clinic expansion tests whether recovery care can scale without losing clinical rigor.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Is Myriad setting a new performance and pricing benchmark in bioscaffold trauma use?
Can Aroa’s bioscaffold platform reshape trauma care economics? See what Myriad’s MASTRR data means for hospitals, surgeons, and reimbursement.
Pharma & Biotech
Is Zegen-15 the breakthrough diabetic foot ulcer therapy insurers will finally cover?
Zegenex, a Pittsburgh-based biotechnology company focused on regenerative wound care, has secured a $215,000 social-impact investment from the Richard King Mellon Foundation to accelerate formulation and preclinical development of Zegen-15, a first-in-class small-molecule cream targeting chronic wounds, including diabetic foot ulcers. The funding positions Zegenex to begin clinical trials by the end of 2026 and